StockData

Invivyd vs Kymera Therapeutics

IVVD and KYMR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IVVD and KYMR compare

Kymera Therapeutics is the larger company, worth 69 times as much as Invivyd ($10.4B against $151M).

Kymera Therapeutics grew revenue faster over the last twelve months (134% versus 26.3% for Invivyd).

Invivyd keeps more of each dollar of sales as profit, with a net margin of −184% compared with −342% at Kymera Therapeutics.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIVVDKYMR
Size and price
Market cap$151M$10.4B
Share price$0.513$121.52
Change, 1 year−78.2%87.1%
Change, 5 years−98.0%126%
Beta (5Y)2.530.59
Employees122238
StockData Score
Total score99
Valuation score3 (better)0
Growth score11
Performance score02 (better)
Health score56 (better)
Dividend score00
Valuation
P/S2.6× (better)101×
P/B0.8× (better)6.4×
FCF yield−72.6%−2.8% (better)
Fair value$0.978$37.15
Margin of safety47.6% (better)−227%
Growth
Revenue growth (TTM)26.3%134% (better)
Revenue growth, 5Y average–2.9%
Profitability
Gross margin–0.00%
Operating margin−193% (better)−396%
Net margin−184% (better)−342%
FCF margin−188% (better)−283%
Return on equity−95.9%−27.3% (better)
Return on invested capital−616%−59.0% (better)
Financial health
Debt / equity0.000.00
Current ratio5.8711.13 (better)
Altman Z-score−4.8639.62 (better)
Piotroski F-score5 (better)4
Dividends and buybacks
Buyback yield−0.26%–
Shareholder yield−0.26%0.00% (better)
Ownership
Held by institutions79.0%114%
Held by insiders16.7%38.3%
Insider net buying, 12 months−$531K (better)−$301M
Short interest, % of float14.7%16.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.